# US 2025/0146912 A1 · Fixative solutions and methods for using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146912 A1
- Document ID: US20250146912A1
- Status: Published application
- Kind: A1
- Application number: 18/840,036
- Filed: 2023-02-21
- Published: 2025-05-08
- Earliest claimed: 2022-02-21
- Applicants: Stichting Radboud Universiteit
- Inventors: Wilhelmus Theodorus Stefanus HUCK; Kinga MATULA; Francesca Maria RIVELLO
- Web page: https://patentgrep.com/patent/US20250146912A1

## CPC

- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- G01N 2001/305: {Fixative compositions}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are an in vitro method for fixating at least one cell, a fixative solution and a method for preparing same. The methods of the invention use or provide a fixative solution that is more stable than solutions from the prior art, and yield a better quality of isolated mRNA and proteins. In addition, excellent results are achieved when primary cells are fixated.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

An in vitro method for fixating at least one cell, wherein said method comprises the step of
a) contacting the at least one cell with a liquid, a compound of Formula I, and a compound of Formula II, so as to form a mixture;
wherein the concentration of the compound of Formula I in said mixture is in a range of from 0.8 mM to 2.4 mM;
wherein the concentration of the compound of Formula II in said mixture is sufficient to dissolve substantially all of the compound of Formula I in said mixture; wherein the compound of Formula I is:
wherein the compound of Formula II is:
wherein R1, R2, and R3 are each independently selected from the group consisting of —C(O)O—N-succinimide, —C(O)F, —C(O)Cl, —C(O)Br, —C(O)—N3, —C(O)O-pentafluorophenyl, —C(O)O—N-benzotriazole, —C(O)O-phthalimide, —C(O)—O—C(O)CH3, —NCS, —NCO, —S(O)2Cl, —S(O)2F, phenylsulfonyl fluoride, phenylsulfonyl chloride, and C2 epoxidyl;
wherein X1, X2, and X3 are each independently selected from the group consisting of C1-C6 alkylene, and phenylene;
wherein Q is a bond or C1-6 alkylene;
wherein Z is heteroaryl or aryl; and
wherein each alkylene, phenylene, heteroaryl, and aryl is optionally substituted.

### Claim 17 (depends on 16)

The in vitro method according to claim 16, wherein in said mixture the mol/mol ratio of the compound of Formula I as compared to the compound of Formula II is at most 2:1.

### Claim 18 (depends on 16)

The in vitro method according to claim 16, wherein the at least one cell is a eukaryotic cell.

### Claim 19 (depends on 16)

The in vitro method according to claim 16, wherein the at least one cell is a primary cell.

### Claim 20 (depends on 16)

The in vitro method according to claim 16, wherein at least 90 vol. % of the liquid is water.

### Claim 21 (depends on 16)

The in vitro method according claim 16, wherein the compound of Formula I is dithiobis(succinimidyl propionate) (DSP).

### Claim 22 (depends on 16)

The in vitro method according to claim 16, wherein the compound of Formula II is succinimidyl 3-(2-pyridyldithio)propionate (SPDP).

### Claim 23 (depends on 16)

The in vitro method according to claim 16, wherein R1, R2, and R3 are each —C(O)O—N-succinimide; wherein each of X1, X2, and X3 are ethylene; wherein Q is a bond; wherein Z is 2-pyridyl; wherein the at least one cell is a primary eukaryotic cell selected from the group consisting of cancer cells, white blood cells, red blood cells, bone marrow cells, vascular endothelial cells, hepatocytes, neurons, glial cells, bronchial endothelial cells, epidermal cells, respiratory interstitial cells, adipocytes, dermal fibroblasts, muscle cells, and germ cells.

### Claim 24

A method for preparing a fixative solution comprising a compound of Formula I and a compound of Formula II, wherein said method comprises the steps of:
a) contacting a compound of Formula I with a solvent, so as to form a first solution;
b) contacting said first solution with a compound of Formula II, so as to form second solution;
c) adding a buffer solution, to the second solution, so as to form the fixative solution;
wherein the concentration of the compound of Formula II in said fixative solution is sufficient to dissolve substantially all of the compound of Formula II in said fixative solution;
wherein the second solution is subjected to mixing, during or upon the addition of the buffer solution;
wherein the buffer solution has a temperature in a range of from 15° C. to 45° C., preferably in a range of from 35° C. to 40° C.;
wherein the compound of Formula I is:
wherein the compound of Formula II is:
wherein R1, R2, and R3 are each independently selected from the group consisting of —C(O)O—N-succinimide, —C(O)F, —C(O)Cl, —C(O)Br, —C(O)—N3, —C(O)O-pentafluorophenyl, —C(O)O—N-benzotriazole, —C(O)O-phthalimide, —C(O)—O—C(O)CH3, —NCS, —NCO, —S(O)2Cl, —S(O)2F, phenylsulfonyl fluoride, phenylsulfonyl chloride, and C2 epoxidyl;
wherein X1, X2, and X3 are each independently selected from the group consisting of C1-C6 alkylene, and phenylene;
wherein Q is a bond or C1-6 alkylene;
wherein Z is heteroaryl or aryl; and
wherein each alkylene, phenylene, heteroaryl, and aryl is optionally substituted.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the compound of Formula I is dithiobis(succinimidyl propionate) (DSP).

### Claim 26 (depends on 24)

The method according to claim 24, wherein the compound of Formula II is succinimidyl 3-(2-pyridyldithio)propionate (SPDP).

### Claim 27 (depends on 24)

The method according to claim 24, wherein in said fixative solution the mol/mol ratio of the compound of Formula I as compared to the compound of Formula II is at most 2:1.

### Claim 28 (depends on 24)

The method according to claim 24, wherein R1, R2, and R3 are each —C(O)O—N-succinimide; wherein each of X1, X2, and X3 are ethylene; wherein Q is a bond; wherein Z is 2-pyridyl.

### Claim 29 (depends on 24)

A fixative solution obtainable by the method according to claim 24.

### Claim 30 (depends on 29)

An in vitro cell fixated with a fixative solution according to claim 29.

### Claim 31 (depends on 30)

The in vitro cell according to claim 30, wherein said in vitro cell is a eukaryotic cell.

### Claim 32 (depends on 30)

The in vitro cell according to claim 30, wherein said in vitro cell is a primary cell.

### Claim 33 (depends on 16)

An in vitro fixed cell obtainable by the in vitro method according to claim 16.

### Claim 34 (depends on 33)

The in vitro fixed cell according to claim 33, wherein said in vitro fixed cell is a eukaryotic cell.

### Claim 35 (depends on 33)

The in vitro fixed cell according claim 33, wherein said in vitro fixed cell is a primary cell.
